SEC Form SC 13G filed by BELLUS Health Inc.

$BLU
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $BLU alert in real time by email
SC 13G 1 formsc13g.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No.)*

 

BELLUS Health Inc.
(Name of Issuer)
 
Common Shares, no par value
(Title of Class of Securities)
 
07987C204
(CUSIP Number)
 
March 20, 2023
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 
 

 

CUSIP No. 07987C204 SCHEDULE 13G  

 

1

NAME OF REPORTING PERSONS

 

Commodore Capital LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐

(b) ☐

3

SEC USE ONLY

 

 

 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware, USA

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

6,579,359*

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

6,579,359*

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

6,579,359*

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.2%*

12

TYPE OF REPORTING PERSON

 

IA

 

*See Item 4 for additional information.

 

 
 

 

CUSIP No. 07987C204 SCHEDULE 13G  

 

1

NAME OF REPORTING PERSONS

 

Commodore Capital Master LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐

(b) ☐

3

SEC USE ONLY

 

 

 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Cayman Islands

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

6,579,359*

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

6,579,359*

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

6,579,359*

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.2%*

12

TYPE OF REPORTING PERSON

 

OO

 

*See Item 4 for additional information.

 

 
 

 

CUSIP No. 07987C204 SCHEDULE 13G  

 

Item 1. (a) Name of Issuer
   
  BELLUS Health Inc. (the “Issuer”)
   
Item 1. (b) Address of Issuer’s Principal Executive Offices
   
  275 Armand-Frappier Blvd., Laval, Quebec H7V 4A7, Canada
   
Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:
   
  This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.
   
Item 2. (d) Title of Class of Securities
   
  Common Shares, no par value (the “Common Stock”)
   
Item 2. (e) CUSIP No.:
   
  07987C204
   
Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:
   
  N/A

 

 
 

 

CUSIP No. 07987C204 SCHEDULE 13G  

 

Item 4. Ownership
   
  As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:
   
  (a) Amount Beneficially Owned: 6,579,359*
  (b) Percent of Class: 5.2%*
  (c) Number of Shares as to which such person has:

 

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 6,579,359*
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 6,579,359*

 

  As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:
   
  (a) Amount Beneficially Owned: 6,579,359*
  (b) Percent of Class: 5.2%*
  (c) Number of Shares as to which such person has:

 

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 6,579,359*
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 6,579,359*

 

*The Firm is the investment manager to Commodore Master. As of March 20, 2023, the Firm may be deemed to beneficially own an aggregate of 6,579,359 shares of Common Stock of the Issuer. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 126,567,121 shares of Common Stock reported as issued and outstanding as of December 31, 2022 in the Issuer’s Annual Report on Form 40-F filed with the Securities and Exchange Commission on March 23, 2023.

 

 
 

 

Item 5. Ownership of Five Percent or Less of a Class
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
   
Item 6. Ownership of More Than Five Percent on Behalf of Another Person
   
  Not Applicable.
   
Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
   
  Not Applicable.
   
Item 8. Identification and Classification of Members of the Group
   
  Not Applicable.
   
Item 9. Notice of Dissolution of Group
   
  Not Applicable.
   
Item 10. Certification
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 
 

 

CUSIP No. 07987C204 SCHEDULE 13G  

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: March 30, 2023

 

Commodore Capital LP  
   
By: /s/ Michael Kramarz  
Michael Kramarz, Managing Partner  
   
Commodore Capital Master LP  
   
By: /s/ Michael Kramarz  
Michael Kramarz, Authorized Signatory  

 

 
 

 

Exhibit 1

 

JOINT FILING AGREEMENT

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate.

 

Dated: March 30, 2023

 

Commodore Capital LP  
     
By: /s/ Michael Kramarz  
  Michael Kramarz, Managing Partner  
     
Commodore Capital Master LP  
     
By: /s/ Michael Kramarz  
  Michael Kramarz, Authorized Signatory  

 

 

Get the next $BLU alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BLU

DatePrice TargetRatingAnalyst
4/19/2023Outperform → Sector Perform
RBC Capital Mkts
2/24/2022$14.00 → $16.00Buy
HC Wainwright & Co.
12/13/2021$12.00 → $20.00Outperform
Evercore ISI Group
12/7/2021$9.00 → $11.00Outperform
RBC Capital
10/18/2021$8.00 → $9.00Outperform
RBC Capital
9/14/2021$10.00 → $14.00Buy
HC Wainwright & Co.
7/29/2021$9.00Buy
BTIG Research
More analyst ratings

$BLU
Press Releases

Fastest customizable press release news feed in the world

See more
  • Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

    LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R

    $BLU
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders

    BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced the positive outcome of the BELLUS shareholders ("Shareholders") vote at this morning's special meeting of the Shareholders (the "Special Meeting") held in-person, approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a corporation existing under the laws of Canada and a wholly-owned subsidiary of GSK plc (NYSE:GSK, LSE: GSK))) ("GSK"), will acquire, for a purchase price of US$14.75 in cash per share, all of the issued and outstanding common shares of BELLUS (the

    $BLU
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition

    Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a co

    $BLU
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BLU
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BLU
SEC Filings

See more

$BLU
Leadership Updates

Live Leadership Updates

See more
  • OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

    NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

    $BLU
    $GKOS
    $INSP
    $NTLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors

    LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast development and commercial experience to the Board, including the development and approval of 30 products across multiple therapeutic areas. “Bill is a biopharmaceutical veteran with a proven drug development track record, including the approval of several drugs within the respiratory field,” c

    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BLU
Financials

Live finance-specific insights

See more
  • Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

    LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R

    $BLU
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

    Primary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p ≤ 0.005) BLU-5937 was well-tolerated with a low rate of taste-related adverse events (≤6.5%); treatment emergent adverse event profile comparable to placebo Company also provides an update on its P2X3 pipeline and BLU-5937 Phase 2a trial for the treatment of chronic pruritus Company to host conference call and webcast at 8:00 a.m. ET BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC"

    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BLU
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more